PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	durvalumab + TEW-7197 Sensitive: C2 – Inclusion Criteria durvalumab + TEW-7197 Sensitive : C2	durvalumab + TEW-7197 Sensitive: C2 – Inclusion Criteria durvalumab + TEW-7197 Sensitive : C2
PRDX1 overexpression	Hepatocellular Cancer	PRDX1 overexpression	Hepatocellular Cancer	LY2109761 Sensitive: C3 – Early Trials LY2109761 Sensitive : C3	LY2109761 Sensitive: C3 – Early Trials LY2109761 Sensitive : C3
NSD3 overexpression	Breast Cancer	NSD3 overexpression	Breast Cancer	LY2109761 Sensitive: D – Preclinical LY2109761 Sensitive : D	LY2109761 Sensitive: D – Preclinical LY2109761 Sensitive : D

TGF-β RI kinase inhibitor

Associations(3)